Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future

Area of Science:

• Immunology
• Hepatology
• Oncology

Background:

• Cancer immunotherapy, particularly T cell therapy, has shown success in treating melanoma and leukemia.
• Engineered T cells expressing T cell receptors (TCRs) or chimeric antigen receptors (CARs) can target specific cancer antigens.
• Persistent viral infections like hepatitis B virus (HBV) and their associated cancers represent a potential area for T cell therapy.

Purpose of the Study:

• To explore the potential of HBV-specific TCR-redirected T cells as an immunotherapy for HBV-related hepatocellular carcinoma (HCC).
• To evaluate the efficacy of targeting hepatitis B viral antigens as tumor-specific antigens in HCC patients.

Main Methods:

• A first-in-man clinical trial was conducted to test HBV-specific TCR-redirected T cells.
• The study assessed the ability of these redirected T cells to target HBsAg-productive HCC cells.

Main Results:

• The engineered T cells successfully recognized HCC cells that had integrated HBV-DNA.
• This demonstrates the feasibility of targeting HBV-infected liver cancer cells with specific T cells.

Conclusions:

• HBV-specific TCR-redirected T cells show potential as a targeted immunotherapy for HBV-related HCC.
• Further development is needed to address challenges in implementing this novel immunotherapeutic strategy.